Mpeg1 in Innate Immunity
Mpeg1 in Innate Immunity
批准号:
8880309
负责人:
ECKHARD R PODACK
金额:
$38.38万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-07-15 至 2015-06-30
关键词:
AbscessAcid Fast Bacillae Staining MethodAnti-Bacterial AgentsAntibiotic ResistanceBacteremiaBacteriaBacterial InfectionsBone MarrowBreedingCell LineageCellsColitisColonCrohn&aposs diseaseCytolysisDataDiarrheaDisease modelEndosomesEpithelialGenerationsGenus MycobacteriumHealthImmune systemIn VitroInfectionInfectious Skin DiseasesInflammationInflammatory Bowel DiseasesInflammatory ResponseIntegral Membrane ProteinKnockout MiceLymphoid CellMeasuresMediatingMembraneMesenchymalModelingMolecularMucosal ImmunityMucous body substanceMuramidaseMusMyeloid CellsNatural ImmunityP-2Partner in relationshipPathogenesisPeritoneal MacrophagesPhagosomesPharmaceutical PreparationsPredispositionProteinsRoleSalmonellaSalmonella infectionsSalmonella typhimuriumSkinSodium Dextran SulfateTestingVacuoleVesicleWaterWeightWorkacid fast bacteriabactericidedrinkingdrug developmentinsightinterestkeratinocytekillingsmethicillin resistant Staphylococcus aureusmicrobiomenovelpathogenic bacteriaperforin 2polymerizationporin
中文摘要
描述(由申请人提供):在这份修订的申请中,我们表明穿孔素-2(Mpeg1)缺陷的小鼠无法清除口胃感染鼠伤寒沙门氏菌和皮肤表面感染耐甲氧西林金黄色葡萄球菌(MRSA)。野生型,穿孔素-2足以清除这两种类型的细菌。这些发现支持我们之前的体外数据,即穿孔素-2对于清除细胞内细菌感染是必不可少的。穿孔素-2在所有来源于内胚层、外胚层、神经外胚层和间充质细胞的细胞中普遍表达:构成或被IFN诱导。我们的数据还表明,杀死细胞内的细菌是细菌感染中观察到的炎症反应的原因,也是细菌清除所必需的。我们在葡聚糖硫酸钠炎症性肠病模型中的新数据表明,P-2负责引起炎症反应,为IBD的发病机制提供了新的见解,这可能对开发克罗恩病的治疗方案很重要。此外,P-2在抗菌防御中的作用为抗耐药细菌感染的药物开发提供了机会。在这项申请中,我们将在三个具体目标上进行工作。在第一个目标中,我们将研究P-2充足和P-2缺乏的小鼠对鼠伤寒沙门氏菌感染的黏膜免疫,并确定与P-2相关的炎症反应的作用和分子机制。在第二个特定目标中,我们将研究P-2在葡聚糖硫酸钠(DSS)疾病模型中诱导腹泻的作用以及P-2在微生物组组成中的作用。第三个目标是研究P-2缺陷小鼠对耐甲氧西林金黄色葡萄球菌(MRSA)的敏感性,并研究P-2介导的MRSA杀伤角质形成细胞的分子机制。
英文摘要
DESCRIPTION (provided by applicant): In this revised application we show that Perforin-2 (Mpeg1) deficient mice are unable to clear orogastric infection with Salmonella typhimurium and epicutaneous infection with methicillin resistant Staphylococcus aureus (MRSA). Wild type, Perforin-2 sufficient littermates clear both types of bacteria. These findings support our previous in vitro data that showed that Perforin-2 is essential for clearing intracellular bacterial infections. Perforin-2 is expressed ubiquitously: constitutive or inducible by IFNs in all cells derived from endodermal, ectodermal, neuroectodermal and mesenchymal cells. Our data also suggest that killing of bacteria inside cells is responsible fo the inflammatory response observed in bacterial infections and required for bacterial clearance. Our new data in the dextran sodium sulfate model of inflammatory bowel disease suggest that P-2 is responsible for causing the inflammatory response providing novel insights into the pathogenesis of IBD which may be important for developing treatment options for Crohn's disease. In addition, the role of P-2 for anti-bacterial defense provides opportunities for drug development against antibiotic resistant bacterial infections. In ths application we will pursue work in three specific aims. In the first aim we will study mucosal immunity in P-2 sufficient and P-2 deficient mice to orogastric infection with Salmonela typhimurium and determine the role and molecular mechanisms of the inflammatory response in relation to P-2. In the second specific aim we will study the role of P-2 in the induction of diarrhea in the disease model of dextran sodium sulfate (DSS) and the role of P-2 in the composition of the microbiome. In the third specific aim, the susceptibility of P-2 deficint mice to methicillin resistant Staphylococcus aureus (MRSA) will be investigated and the molecular mechanism of P-2 mediated killing of MRSA in keratinocytes studied.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Response to and protection by gp96SIVIg/TNFSF13 and gp96SIVIg/TNFSF15 vaccines
-
批准号:8198211
-
项目类别:
-
资助金额:$37.17万
-
财政年份:2011
-
负责人:ECKHARD R PODACK
-
依托单位:
Generation of gp96SIVIg/TNFSF13 and gp96SIVIg/TNFSF15 vaccinesVaccines
-
批准号:8198209
-
项目类别:
-
资助金额:$32.98万
-
财政年份:2011
-
负责人:ECKHARD R PODACK
-
依托单位:
Mechanisms of mucosal protection by HPV-SIV and gp96-lg-SIV vaccines
-
批准号:8193660
-
项目类别:
-
资助金额:$200.0万
-
财政年份:2011
-
负责人:ECKHARD R PODACK
-
依托单位:
Induction of mucosal SIV immunity in non human primates by secreted Hsp-Gp96
-
批准号:7911001
-
项目类别:
-
资助金额:$34.9万
-
财政年份:2009
-
负责人:ECKHARD R PODACK
-
依托单位:
REGULATION OF ANTI-TUMOR IMMUNITY
-
批准号:7619044
-
项目类别:
-
资助金额:$120.05万
-
财政年份:2007
-
负责人:ECKHARD R PODACK
-
依托单位:
REGULATION OF ANTI-TUMOR IMMUNITY
-
批准号:8058779
-
项目类别:
-
资助金额:$116.12万
-
财政年份:2007
-
负责人:ECKHARD R PODACK
-
依托单位:
Induction of mucosal SIV immunity in non human primates by secreted Hsp-Gp96
-
批准号:7786796
-
项目类别:
-
资助金额:$45.9万
-
财政年份:2007
-
负责人:ECKHARD R PODACK
-
依托单位:
REGULATION OF ANTI-TUMOR IMMUNITY
-
批准号:7797030
-
项目类别:
-
资助金额:$8.57万
-
财政年份:2007
-
负责人:ECKHARD R PODACK
-
依托单位:
REGULATION OF ANTI-TUMOR IMMUNITY
-
批准号:7683414
-
项目类别:
-
资助金额:$6.02万
-
财政年份:2007
-
负责人:ECKHARD R PODACK
-
依托单位:
REGULATION OF ANTI-TUMOR IMMUNITY
-
批准号:7408553
-
项目类别:
-
资助金额:$116.92万
-
财政年份:2007
-
负责人:ECKHARD R PODACK
-
依托单位:
REGULATION OF ANTI-TUMOR IMMUNITY
-
批准号:8138249
-
项目类别:
-
资助金额:$4.23万
-
财政年份:2007
-
负责人:ECKHARD R PODACK
-
依托单位:
REGULATION OF ANTI-TUMOR IMMUNITY
-
批准号:7799167
-
项目类别:
-
资助金额:$121.94万
-
财政年份:2007
-
负责人:ECKHARD R PODACK
-
依托单位:
REGULATION OF ANTI-TUMOR IMMUNITY
-
批准号:8244633
-
项目类别:
-
资助金额:$2.57万
-
财政年份:2007
-
负责人:ECKHARD R PODACK
-
依托单位:
Induction of mucosal SIV immunity in non human primates by secreted Hsp-Gp96
-
批准号:7382544
-
项目类别:
-
资助金额:$18.6万
-
财政年份:2007
-
负责人:ECKHARD R PODACK
-
依托单位:
Induction of mucosal SIV immunity in non human primates by secreted Hsp-Gp96
-
批准号:7808837
-
项目类别:
-
资助金额:$45.44万
-
财政年份:2007
-
负责人:ECKHARD R PODACK
-
依托单位:
Induction of mucosal SIV immunity in non human primates by secreted Hsp-Gp96
-
批准号:8052718
-
项目类别:
-
资助金额:$44.7万
-
财政年份:2007
-
负责人:ECKHARD R PODACK
-
依托单位:
REGULATION OF ANTI-TUMOR IMMUNITY
-
批准号:7193080
-
项目类别:
-
资助金额:$122.38万
-
财政年份:2007
-
负责人:ECKHARD R PODACK
-
依托单位:
Induction of mucosal SIV immunity in non human primates by secreted Hsp-Gp96
-
批准号:7230681
-
项目类别:
-
资助金额:$22.93万
-
财政年份:2007
-
负责人:ECKHARD R PODACK
-
依托单位:
Administration Core
-
批准号:7226414
-
项目类别:
-
资助金额:$9.39万
-
财政年份:2006
-
负责人:ECKHARD R PODACK
-
依托单位:
Systemic and Mucosal HIV-Immunity by Hsp-Gp96 Vaccines
-
批准号:7230038
-
项目类别:
-
资助金额:$22.28万
-
财政年份:2006
-
负责人:ECKHARD R PODACK
-
依托单位: